Animal models of pulmonary hypertension: Getting to the heart of the problem
JP Dignam, TE Scott, BK Kemp‐Harper… - British Journal of …, 2022 - Wiley Online Library
Despite recent therapeutic advances, pulmonary hypertension (PH) remains a fatal disease
due to the development of right ventricular (RV) failure. At present, no treatments targeted at …
due to the development of right ventricular (RV) failure. At present, no treatments targeted at …
Recent developments in nanomaterials-based drug delivery and upgrading treatment of cardiovascular diseases
Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality
worldwide. However, despite the recent developments in the management of CVDs, the …
worldwide. However, despite the recent developments in the management of CVDs, the …
Treating inflammation associated with pulmonary hypertension: an overview of the literature
HHB Yoo, FL Marin - International Journal of General Medicine, 2022 - Taylor & Francis
Pulmonary hypertension (PH) comprises five groups of serious clinical entities characterized
by pulmonary artery vasoconstriction and vascular remodeling leading to right heart failure …
by pulmonary artery vasoconstriction and vascular remodeling leading to right heart failure …
Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-β signalling
K Kurakula, QAJ Hagdorn, DE van der Feen… - Angiogenesis, 2022 - Springer
Pulmonary arterial hypertension (PAH) is a devastating disease, characterized by
obstructive pulmonary vascular remodelling ultimately leading to right ventricular (RV) …
obstructive pulmonary vascular remodelling ultimately leading to right ventricular (RV) …
The glycobiology of pulmonary arterial hypertension
S Vang, P Cochran, J Sebastian Domingo, S Krick… - Metabolites, 2022 - mdpi.com
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease of
complex etiology. Cases of PAH that do not receive therapy after diagnosis have a low …
complex etiology. Cases of PAH that do not receive therapy after diagnosis have a low …
Metabolic reprogramming: A novel metabolic model for pulmonary hypertension
X Liu, L Zhang, W Zhang - Frontiers in Cardiovascular Medicine, 2022 - frontiersin.org
Pulmonary arterial hypertension, or PAH, is a condition that is characterized by pulmonary
artery pressures above 20 mmHg (at rest). In the treatment of PAH, the pulmonary vascular …
artery pressures above 20 mmHg (at rest). In the treatment of PAH, the pulmonary vascular …
Computational models of ventricular mechanics and adaptation in response to right-ventricular pressure overload
OO Odeigah, D Valdez-Jasso, ST Wall… - Frontiers in …, 2022 - frontiersin.org
Pulmonary arterial hypertension (PAH) is associated with substantial remodeling of the right
ventricle (RV), which may at first be compensatory but at a later stage becomes detrimental …
ventricle (RV), which may at first be compensatory but at a later stage becomes detrimental …
Pyrroloquinoline quinone (PQQ) improves pulmonary hypertension by regulating mitochondrial and metabolic functions
M Shafiq, ZR Lone, P Bharati, S Mahapatra… - Pulmonary …, 2022 - Elsevier
Excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) and endothelial
cells (PAECs), inflammation, as well as mitochondrial and metabolic dysregulation …
cells (PAECs), inflammation, as well as mitochondrial and metabolic dysregulation …
[HTML][HTML] IL-13 alleviates idiopathic pulmonary hypertension by inhibiting the proliferation of pulmonary artery smooth muscle cells and regulating macrophage …
R Wei, L Chen, P Li, C Lin, Q Zeng - American Journal of …, 2022 - ncbi.nlm.nih.gov
Background: Idiopathic pulmonary arterial hypertension (IPAH) is characterized by medial
hypertrophy due to pulmonary artery smooth muscle cell (PASMC) hyperplasia. In the …
hypertrophy due to pulmonary artery smooth muscle cell (PASMC) hyperplasia. In the …
Insights on the gut-mesentery-lung axis in pulmonary arterial hypertension: a poorly investigated crossroad
SD Oliveira - Arteriosclerosis, thrombosis, and vascular biology, 2022 - Am Heart Assoc
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by the
hyperproliferation of vascular cells, including smooth muscle and endothelial cells …
hyperproliferation of vascular cells, including smooth muscle and endothelial cells …